Oncolytics Biotech (ONC) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock ONC vs. BLU, TRIL, CXR, FRX, PLI, ABCN, EMC, TH, BCT, and IPAShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include BELLUS Health (BLU), Trillium Therapeutics (TRIL), Concordia International (CXR), Fennec Pharmaceuticals (FRX), ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Theratechnologies (TH), BriaCell Therapeutics (BCT), and ImmunoPrecise Antibodies (IPA). These companies are all part of the "biotechnology" industry. Oncolytics Biotech vs. Its Competitors BELLUS Health Trillium Therapeutics Concordia International Fennec Pharmaceuticals ProMetic Life Sciences VIVO Cannabis Emblem Theratechnologies BriaCell Therapeutics ImmunoPrecise Antibodies Oncolytics Biotech (TSE:ONC) and BELLUS Health (TSE:BLU) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings. Does the media refer more to ONC or BLU? In the previous week, Oncolytics Biotech had 2 more articles in the media than BELLUS Health. MarketBeat recorded 2 mentions for Oncolytics Biotech and 0 mentions for BELLUS Health. BELLUS Health's average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.66 indicating that BELLUS Health is being referred to more favorably in the news media. Company Overall Sentiment Oncolytics Biotech Negative BELLUS Health Neutral Which has more volatility and risk, ONC or BLU? Oncolytics Biotech has a beta of 0.795238, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, BELLUS Health has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Do analysts prefer ONC or BLU? Oncolytics Biotech presently has a consensus target price of C$3.50, indicating a potential upside of 0.00%. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00BELLUS Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, ONC or BLU? Oncolytics Biotech has higher earnings, but lower revenue than BELLUS Health. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-C$27.66M-C$0.37N/ABELLUS HealthC$16K0.00-C$86.79M-C$0.96N/A Is ONC or BLU more profitable? BELLUS Health's return on equity of -26.76% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.94% -71.33% BELLUS Health N/A -26.76%-16.70% Do institutionals and insiders believe in ONC or BLU? 0.1% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 90.4% of BELLUS Health shares are owned by institutional investors. 3.8% of Oncolytics Biotech shares are owned by insiders. Comparatively, 10.3% of BELLUS Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryBELLUS Health beats Oncolytics Biotech on 7 of the 13 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricOncolytics BiotechBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$1.50BC$236.98MC$5.85BC$9.39BDividend Yield0.31%3.78%5.68%6.51%P/E Ratio-40.2741.0875.3425.78Price / SalesN/A5,000.68514.559.40Price / Cash4.2213.1937.5683.29Price / BookN/A103.7512.155.54Net Income-C$27.66M-C$90.99MC$3.29BC$301.20M7 Day PerformanceN/A2.90%0.74%1.42%1 Month Performance964.29%21.06%4.82%7.75%1 Year Performance1,046.15%530.97%60.58%36.81% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncolytics Biotech1.6416 of 5 starsN/AC$3.50+∞+1,037.4%C$1.50BN/A-40.2729BLUBELLUS HealthN/AN/AN/AN/AC$2.47BC$16K-20.2974TRILTrillium TherapeuticsN/AN/AN/AN/AC$2.45BC$43K-34.0633CXRConcordia InternationalN/AN/AN/AN/AC$1.22BC$569.62M0.0722,500High Trading VolumeFRXFennec PharmaceuticalsN/AC$12.19-1.7%N/A+74.4%C$339.27MC$33.30M-27.0910News CoveragePLIProMetic Life SciencesN/AN/AN/AN/AC$317.06MC$39.91M-0.22487ABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/ATHTheratechnologiesN/AC$4.55+0.7%N/A+172.0%C$209.21MC$84.38M-23.95103News CoverageBCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195Negative NewsIPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap Down Related Companies and Tools Related Companies BELLUS Health Alternatives Trillium Therapeutics Alternatives Concordia International Alternatives Fennec Pharmaceuticals Alternatives ProMetic Life Sciences Alternatives VIVO Cannabis Alternatives Emblem Alternatives Theratechnologies Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:ONC) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONC Stock Alerts